Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
Phase of Trial: Phase I/II
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BMS # CA209-632
- 31 Aug 2018 Biomarkers information updated
- 18 Aug 2017 Status changed from not yet recruiting to recruiting.
- 08 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.